Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Odefsey emtricitabine/rilpivirine/ tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Odomzo Sonidegib Basal Cell Carcinoma Do not reimburse Complete
Ofev nintedanib chronic fibrosing interstitial lung diseases Reimburse with clinical criteria and/or conditions Complete
Ofev Nintedanib Idiopathic pulmonary fibrosis List with clinical criteria and/or conditions Complete
Ogivri Trastuzumab Withdrawn
Olmetec Olmesartan medoxomil Hypertension List in a similar manner to other drugs in class Complete
Olmetec Plus Olmesartan medoxomil + hydrochlorothiazide Hypertension List in a similar manner to other drugs in class Complete
Olumiant baricitinib Alopecia areata, severe Reimburse with clinical criteria and/or conditions Active
Olumiant baricitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete
Omnaris Ciclesonide nasal spray Allergic Rhinitis (seasonal and perennial) Do not list Complete